Medicinal products for human use: transparency of measures regulating the prices and their inclusion in the scope of public health insurance systems

The dossier concerns transparency of measures regulating the prices of medicinal products for human use and their inclusion in public health insurance systems. The amendments address marketing authorisation holders' applications to approve or increase prices, time limits for decisions, derogations from price freezes or reductions, statements of reasons, remedies, and disclosure of experts in pricing and reimbursement bodies; some reject the Commission proposal.